![Sandipkumar S. Kapadia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sandipkumar S. Kapadia
President chez
ZYNERBA PHARMACEUTICALS, INC.
Fortune : 810 979 $ au 31/05/2026
Profil
Sandipkumar S.
Kapadia currently serves as Independent Non-Executive Director at Molecular Partners AG since 2020 and at Passage Bio, Inc. since 2019.
Holds director positions at Intercept Pharma Europe Ltd., Molecular Partners, Inc., and Alentis Therapeutics AG.
Serves as President of Harmony Biosciences Management, Inc. Former roles include Director at Intercept Pharma UK & Ireland Ltd. (2017–2021), Co-Managing Director at Advanz Pharma Specialty Medicine Deutschland GmbH, Director at Therachon AG, Independent Director at VectivBio Holding AG (2020–2023), Director at VectivBio AG (2020–2023), Chief Financial Officer & Vice President at Sandoz, Inc. (2014–2016), Chief Financial Officer & Treasurer at Intercept Pharmaceuticals, Inc. (2016–2021), Chief Financial Officer & Vice President at Novartis Pharmaceuticals UK Ltd. and Novartis Pharmaceuticals BV (2009–2012), Head-Finance at Novartis Pharmaceuticals Corp.
and Novartis Pharmaceuticals AG, Member-Supervisory Board at Therachon Holding GmbH, Chief Financial Officer at Harmony Biosciences LLC (2021–2026), and Chief Financial & Administrative Officer at Harmony Biosciences Holdings, Inc. (2023–2026).
Education includes an MBA from Rutgers State University of New Jersey and undergraduate studies at Montclair State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 17/03/2026 | 24 521 ( 0,04 % ) | 774 618 $ | 31/05/2026 | |
MOLECULAR PARTNERS AG 0,02 % | 31/12/2025 | 9 048 ( 0,02 % ) | 36 361 $ | 31/05/2026 |
PASSAGE BIO, INC. -.--% | 19/05/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Sandipkumar S. Kapadia
| Sociétés | Poste | Début |
|---|---|---|
| PASSAGE BIO, INC. | Directeur/Membre du Conseil | 01/12/2019 |
| MOLECULAR PARTNERS AG | Directeur/Membre du Conseil | 01/04/2020 |
| ZYNERBA PHARMACEUTICALS, INC. | President | - |
Alentis Therapeutics AG
 Alentis Therapeutics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapies to treat cancer and reverse fibrosis | Directeur/Membre du Conseil | - |
Molecular Partners, Inc.
 Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Directeur/Membre du Conseil | - |
Intercept Pharma Europe Ltd.
 Intercept Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Researches, develops and sells pharmaceutical products | Directeur/Membre du Conseil | 28/09/2016 |
Anciens postes connus de Sandipkumar S. Kapadia
| Sociétés | Poste | Fin |
|---|---|---|
Harmony Biosciences LLC
 Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for people living with rare neurological disorders | Directeur Financier/CFO | 15/04/2026 |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Directeur Financier/CFO | 14/04/2026 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology Operates as biotechnology company | Directeur/Membre du Conseil | 01/07/2023 |
| ░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Sandipkumar S. Kapadia
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
24
Relations au 1er degré
22
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 22 |
|---|---|
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes generic pharmaceutical products | Health Technology |
Intercept Pharmaceuticals, Inc.
 Intercept Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases | Health Technology |
Zynerba Pharmaceuticals, Inc.
 Zynerba Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Delivers dermal solutions for the treatment of neuroscience disorders | Health Technology |
Novartis Pharmaceuticals UK Ltd.
 Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Manufactures medicines and drugs | Health Technology |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Montclair State University
 Montclair State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Health Technology |
Molecular Partners AG
 Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
Novartis Pharmaceuticals AG | |
Harmony Biosciences Holdings, Inc.
 Harmony Biosciences Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for patients living with rare neurological disorders | Health Technology |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for people living with rare neurological disorders | Health Technology |
Novartis Pharmaceuticals BV
 Novartis Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Therachon Holding GmbH
 Therachon Holding GmbH BiotechnologyHealth Technology Develops medical treatments for rare conditions | Health Technology |
Passage Bio, Inc.
 Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Alentis Therapeutics AG
Alentis Therapeutics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapies to treat cancer and reverse fibrosis | Health Technology |
Intercept Pharma Europe Ltd.
Intercept Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Researches, develops and sells pharmaceutical products | Commercial Services |
Intercept Pharma UK & Ireland Ltd.
 Intercept Pharma UK & Ireland Ltd. Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
Intercept Pharma Deutschland GmbH
 Intercept Pharma Deutschland GmbH Medical DistributorsDistribution Services Sells pharmaceutical products and provides marketing support services | Distribution Services |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Therachon AG | |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for rare diseases | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
